These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7168944)

  • 1. [Pathophysiological mechanisms of adverse effects from levodopa therapy].
    Fahn S
    Rinsho Shinkeigaku; 1982 Dec; 22(12):1088-91. PubMed ID: 7168944
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa for the treatment of Parkinson's disease.
    Lewitt PA
    N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127
    [No Abstract]   [Full Text] [Related]  

  • 3. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 4. Levodopa in the treatment of Parkinson's disease.
    Lloyd KG
    Prim Care; 1977 Sep; 4(3):541-60. PubMed ID: 264229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risks of modern therapy for parkinsonism, and their consequences (author's transl)].
    Jörg J; Kleine D
    Nervenarzt; 1979 Jan; 50(1):33-42. PubMed ID: 424033
    [No Abstract]   [Full Text] [Related]  

  • 8. [Parkinson's disease and neurotransmitters].
    Narabayashi H
    Nihon Rinsho; 1984 Apr; 42(4):869-74. PubMed ID: 6481982
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopaminergic drugs in development for Parkinson's disease.
    Korczyn AD
    Adv Neurol; 2003; 91():267-71. PubMed ID: 12442685
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopaminergic supersensitivity in parkinsonism.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    Adv Neurol; 1975; 9():121-9. PubMed ID: 1146650
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
    Crossman AR
    Mov Disord; 1990; 5(2):100-8. PubMed ID: 1970120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 14. The history of dopamine and levodopa in the treatment of Parkinson's disease.
    Fahn S
    Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relief of parkinsonism and dyskinesia: one and the same dopaminergic mechanism?
    Lewitt PA
    Neurology; 2010 Apr; 74(15):1169-70. PubMed ID: 20237309
    [No Abstract]   [Full Text] [Related]  

  • 16. Induction of mania by L-dopa in a nonbipolar patient.
    Harsch HH; Miller M; Young LD
    J Clin Psychopharmacol; 1985 Dec; 5(6):338-9. PubMed ID: 4066999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extrapyramidal and presenile dementia. Relation between symptoms of dementia and cerebral transmitters, particularly dopamine].
    Kristensen V
    Ugeskr Laeger; 1976 Aug; 138(34):2047-50. PubMed ID: 184570
    [No Abstract]   [Full Text] [Related]  

  • 18. Position of COMT inhibition in the treatment of Parkinson's disease.
    Gordin A; Kaakkola S; Teräväinen H
    Adv Neurol; 2003; 91():237-50. PubMed ID: 12442682
    [No Abstract]   [Full Text] [Related]  

  • 19. [L-dopa treatment in parkinsonism. Biochemical basis (author's transl)].
    Bieniowa A; Kolasa M; Reichowa J
    Przegl Lek; 1976; 33(4):463-7. PubMed ID: 1273343
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.